uniQure (NASDAQ:QURE) Stock Rating Lowered by Wall Street Zen

uniQure (NASDAQ:QURE) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of uniQure in a report on Friday, June 26th. Wells Fargo & Company raised their price target on shares of uniQure from $60.00 to $75.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. William Blair initiated coverage on shares of uniQure in a research report on Wednesday, September 2nd. They issued an “outperform” rating on the stock. HC Wainwright upped their price objective on shares of uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Barclays lowered their price objective on shares of uniQure from $65.00 to $60.00 and set an “overweight” rating for the company in a research note on Thursday, July 30th. Fourteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and a consensus target price of $65.00.

uniQure Price Performance

Shares of uniQure stock opened at $44.50 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. The business’s 50 day simple moving average is $44.30 and its two-hundred day simple moving average is $30.41. The stock has a market capitalization of $3.09 billion, a P/E ratio of -11.10 and a beta of 0.94. uniQure has a one year low of $8.73 and a one year high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The company had revenue of $5.84 million for the quarter, compared to analysts’ expectations of $5.45 million. During the same period last year, the company posted ($0.69) EPS. Analysts forecast that uniQure will post -3.82 EPS for the current year.

Insider Activity at uniQure

In related news, Director Madhavan Balachandran sold 11,685 shares of uniQure stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total value of $526,526.10. Following the sale, the director owned 43,254 shares in the company, valued at $1,949,025.24. The trade was a 21.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kylie O’Keefe sold 15,936 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $431,228.16. Following the transaction, the insider directly owned 108,864 shares in the company, valued at approximately $2,945,859.84. The trade was a 12.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 385,584 shares of company stock valued at $16,737,722 over the last 90 days. Company insiders own 4.65% of the company’s stock.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently modified their holdings of QURE. Avoro Capital Advisors LLC raised its stake in uniQure by 38.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after buying an additional 1,705,556 shares in the last quarter. State Street Corp boosted its position in uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after acquiring an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after acquiring an additional 1,785,275 shares during the period. California State Teachers Retirement System grew its holdings in shares of uniQure by 6,641.2% during the 2nd quarter. California State Teachers Retirement System now owns 2,423,263 shares of the biotechnology company’s stock worth $111,615,000 after acquiring an additional 2,387,316 shares during the period. Finally, Orbimed Advisors LLC raised its position in shares of uniQure by 189.7% in the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after acquiring an additional 1,398,749 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.